Abstract:

Aim: We aimed to investigate the value of Class II fibrosis markers as predictors of liver disease progress, and changes in platelet parameters in the laboratory tests of patients with Hepatitis C virus infection [anti-HCV (+)]admitted to the Somalia Mogadishu Hospital. Material and Methods: All patients older than 18 years old, who were examined in our hospital’s were included in the study. Accompanied by CBC and biochemical measurement results from patients, indirect liver fibrosis (Class II) markers AAR (AST/ALT ratio), APRI (AST/Plt ratio index) and FIB-4 index (Age (year) x AST (U/L) / [Platelet count (109 / L)] x (ALT) 1/2 (U / L)], MPV/Platelet ratio, APRI = [(person AST/AST reference upper limit) x Platelet (103 /ml) x 100] were calculated. Results: A total of 2,887 patients, 1,605 (55.6%) male and 1,282 (44.4%) female, with a median age of 51 (32-67) years, were included in our study. The anti-HCV positivity rate was found to be 1.5 times higher in men than women.APRI, MPV / Plt R and RPR levels, indirect markers of liver damage, were found to be higher in patients with anti-HCV (+) than those in the control group (p<0.001).The median FIB-4 value of anti HCV (+) patients was found to be 1.94 (0.07-297.41). Conclusion: We think that APRI, MPR, the MPV/Plt ratio and FIB-4 biomarkers in particularare useful tests in indicating fibrosis and in predicting its severity in patients with anti-HCV (+) in the Sub-Saharan Africa region.